Clinical Trials Logo

Pulmonary Embolism (PE) clinical trials

View clinical trials related to Pulmonary Embolism (PE).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03595891 Completed - Clinical trials for Pulmonary Thromboembolism

The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

Start date: January 20, 2017
Phase:
Study type: Observational

A study based on a chart review of participants that presented with a sudden blood clot in the lung

NCT ID: NCT02744092 Completed - Cancer Clinical Trials

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

CANVAS
Start date: December 13, 2016
Phase: N/A
Study type: Interventional

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

NCT ID: NCT02523937 Completed - Clinical trials for Deep Vein Thrombosis (DVT)

Evaluation of Soluble Fibrin in Thrombosis Exclusion

FSET
Start date: September 2015
Phase:
Study type: Observational

The purpose of the study is to evaluate the performances of Soluble Fibrin assay for exclusion of Pulmonary Embolism and Deep Venous Thrombosis. Secondary objectives are to determine the threshold value from the ROC curves, the possible interest in the positive diagnosis of Venous Thromboembolism (VTE), and to verify the absence of influence of age on the SF results.

NCT ID: NCT02438462 Completed - Clinical trials for Pulmonary Embolism (PE)

Soluble Fibrin for Diagnosing Pulmonary Embolism

SOFIE
Start date: June 2015
Phase:
Study type: Observational

The purpose of the study is to evaluate the performances of Soluble Fibrin for diagnosing Pulmonary Embolism. Secondary objective is to compare the diagnostic performances of the Soluble Fibrin Assay and the D-Dimer test.

NCT ID: NCT02210819 Completed - Clinical trials for Deep Vein Thrombosis (DVT)

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

XALIA LEA
Start date: June 27, 2014
Phase:
Study type: Observational

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute venous thoromboembolism (VTE). The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute VTE in routine clinical practice.

NCT ID: NCT02073682 Completed - Cancer Clinical Trials

Cancer Venous Thromboembolism (VTE)

Start date: July 16, 2015
Phase: Phase 3
Study type: Interventional

The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.

NCT ID: NCT00986154 Completed - Clinical trials for Venous Thromboembolism

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Start date: October 2009
Phase: Phase 3
Study type: Interventional

Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.

NCT ID: NCT00358735 Completed - Bleeding Clinical Trials

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

SAFE
Start date: June 2006
Phase: N/A
Study type: Interventional

Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.